Capsules (e.g., Of Gelatin, Of Chocolate, Etc.) Patents (Class 424/451)
  • Patent number: 10709700
    Abstract: The present invention relates to a pharmaceutical formulation which provides for extended release of an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: July 14, 2020
    Assignee: Orphazyme A/S
    Inventors: Anders Mørkeberg Hinsby, Thomas Kirkegaard Jensen, Gert Mads Bolwig, Carlos Roberto Camozzi
  • Patent number: 10695431
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: June 30, 2020
    Assignee: Infirst Healthcare Limited
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
  • Patent number: 10695432
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a severe pain in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: June 30, 2020
    Assignee: Infirst Healthcare Limited
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
  • Patent number: 10688059
    Abstract: An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain (a) a solid core containing the L-carnitine, (b) a subcoating containing a cellulosic water soluble polymer over the core, and (c) an enteric coating over the subcoating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: June 23, 2020
    Assignee: Physician's Seal, LLC
    Inventors: Syed M. Shah, Noreen Hassan
  • Patent number: 10675277
    Abstract: Disclosed herein are pharmaceutically acceptable complex formulations comprising complexes of Ivacaftor, or a salt or derivative thereof, together with complexation agents and pharmaceutically acceptable excipients; processes for the preparation thereof; and pharmaceutical compositions containing them. The complexes possess instantaneous redispersibility, increased apparent solubility and permeability compared to KALYDECO, no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex Ivacaftor in solution form.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: June 9, 2020
    Assignee: NanGenex Nanotechnology Incorporated
    Inventors: Richárd Balázs Kárpáti, Gergo Patyi, Orsolya Basa-Dénes, Erzsébet Réka Angi, Tamás Jordán, Tamás Solymosi, Hristos Glavinas, Genovéva Filipcsei
  • Patent number: 10668431
    Abstract: A free standing liquid membrane is disclosed that can selectively separate objects based on the kinetic energy value of the objects such that either an object having a first kinetic energy value can pass through the free standing liquid membrane while retaining the membrane and/or an object having a second kinetic energy value is prevented from passing through the membrane while retaining the membrane. Advantageously, the free standing liquid membrane can remain intact for seconds to hours with multiple objects passing through the membrane.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: June 2, 2020
    Assignee: The Penn State Research Foundation
    Inventors: Tak-Sing Wong, Birgitt Boschitsch
  • Patent number: 10632094
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: April 28, 2020
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
  • Patent number: 10617608
    Abstract: The present invention relates to a composition for a hydrogel sheet including a cellulose ether, a gelling agent, and a gelling promoter, a hydrogel sheet prepared therefrom, and a method of preparing the hydrogel sheet. According to the present invention, the composition for a hydrogel sheet can be used to prepare a hydrogel sheet capable of maintaining the shape thereof without a support by limiting a type of the gelling agent and/or a viscosity of the cellulose ether included in the composition.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: April 14, 2020
    Assignee: LOTTE FINE CHEMICAL CO., LTD.
    Inventors: Ju Hee Shin, Ji Seon Jeong, Sung Hwan Bang, Ju Young Jung
  • Patent number: 10617666
    Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: April 14, 2020
    Inventors: Dania Birte Reiche, Silke Haag-Diergarten, Leah Jeanette Hennings, Saskia Kley, Anne M. Traas
  • Patent number: 10610541
    Abstract: A composition which comprises a prebiotic or a mixture thereof that, upon application to an individual's skin, has a beneficial effect on the skin and that is incorporated in the composition in the form of a multiplicity of tiny beads which comprise, in addition to the prebiotic, a matrix-forming agent, for example, mannitol and hydroxypropyl methylcellulose, and a filler, for example, microcrystalline cellulose, and a personal care composition which includes the beads.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: April 7, 2020
    Assignee: VANTAGE SPECIALTIES, INC.
    Inventor: Giorgio Dell'Acqua
  • Patent number: 10610528
    Abstract: Oral film dosage forms that provide improved solubilization and stabilization of an active ingredient in particle form include at least one primary crystallization inhibitor in an amount that inhibits growth and/or agglomeration of the active ingredient, a polyoxyethylated fatty acid glycerides in an amount that further enhances inhibition of crystallization, growth and agglomeration of the particles of the pharmaceutically active ingredient; and at least one plasticizer present in an amount that is effective to increase flexibility and elasticity of the film dosage form.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: April 7, 2020
    Assignee: Intelgenx Corp.
    Inventors: Horst G. Zerbe, Nadine Paiement, Angela Angusti, Cormac Long, Rodolphe Obeid, Laetitia Rodes, Billal Tir
  • Patent number: 10588932
    Abstract: The present invention relates to a use of a banana stamen extract for promoting hair growth. The banana stamen extract according to the present invention promotes gene expression of VEGF and IGF1 to enhance the proliferation level of hair follicles, so that the density of hairs grown is increased. In addition, the banana stamen extract also inhibits gene expression of SRD5A1, SRDA2 and AR to decrease hair loss, and promote the gene expression of KROX20 so as to significantly enhance hair growth.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: March 17, 2020
    Assignee: TCI CO., LTD.
    Inventors: Yung-Hsiang Lin, Yu-Ting Lin
  • Patent number: 10576042
    Abstract: The present disclosure relates to a composition of at least one predominantly positively charged polyelectrolyte polymer and at least one predominantly negatively charged polyelectrolyte polymer, a preferred composition comprises poly-L-lysine and a gellan gum, preferably a methacrylate gellan gum. The present subject-matter further relates to methods for generating composition of the present disclosure and to uses of a mixture according to the disclosure for biomedical applications such as cellular and acellular systems for tissue engineering and regenerative medicine applications or as drug delivery systems, for the treatment of several diseases namely diabetes mellitus.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: March 3, 2020
    Assignee: ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING CELL BASED TECHNOLOGIES & THERAPIES ASSOCIAÇAO
    Inventors: Silvia Cristina Araújo Vieira, Joaquim Miguel Antunes De Oliveira, Rui Luís Gonçalves Dos Reis, Joana Catarina Da Silva Correia
  • Patent number: 10568893
    Abstract: Methods of treating, reducing, or preventing a disease or symptom relating to a disease such as oral mucositis, gingivitis, periodontitis, gastric mucositis, inflammatory fibrosis, gastritis, colitis, ileitis, Crohn's disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac disease, ulcerative colitis, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer, a gastrointestinal ulcer, an autoimmune disorder, inflammation associated with cancer, cancer treatment, or radiation, and/or pain that include: identifying a patient in need of treatment; and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: February 25, 2020
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Paul B. Savage, Carl Genberg
  • Patent number: 10561631
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: February 18, 2020
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Patent number: 10555902
    Abstract: The present invention relates to a solid pharmaceutical dosage forms and methods for preparing the solid pharmaceutical dosage form that contains fingolimod or its pharmaceutically acceptable salts, conjugates or complexes thereof. The solid pharmaceutical dosage forms may rapidly disintegrates in a patient's oral cavity.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: February 11, 2020
    Assignee: Handa Pharmaceuticals LLC
    Inventor: Fangyu Liu
  • Patent number: 10548892
    Abstract: Embodiments of this invention provide compositions and methods for therapeutic use of diketopiperazines including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat symptoms of Autism Spectrum Disorders and Neurodevelopmental Disorders as well as manufacture of medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: February 4, 2020
    Assignee: NEUREN PHARMACEUTICALS LIMITED
    Inventors: Lawrence Irwin Glass, Michael John Bickerdike, Michael Frederick Snape, Patricia Perez De Cogram
  • Patent number: 10537551
    Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: January 21, 2020
    Assignee: Saniona A/S
    Inventors: Peter G. Nielsen, Mikael S. Thomsen, Bent Højgaard
  • Patent number: 10525033
    Abstract: Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: January 7, 2020
    Assignee: Acacia Pharma Limited
    Inventors: Julian Clive Gilbert, Robert William Gristwood, Nicola Cooper, Gabriel Fox
  • Patent number: 10512625
    Abstract: A topical pharmaceutical composition containing diacerein and/or its analogs is provided. Also provided is a method for treating various diseases using this topical pharmaceutical composition.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: December 24, 2019
    Assignee: TWI BIOTECHNOLOGY, INC.
    Inventors: Chih-Kuang Chen, Jing-Yi Lee, Wei-Shu Lu, Carl Oscar Brown, III
  • Patent number: 10507181
    Abstract: Disclosed herein are compositions and methods for treating lung disorders including lung tumors by pulmonary administration of compositions comprising taxane particles such as docetaxel or paclitaxel particles.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: December 17, 2019
    Assignee: Crititech, Inc.
    Inventors: Michael Baltezor, Matthew McClorey, William Johnston, Gere S. diZerega, James Verco
  • Patent number: 10493048
    Abstract: Provided herein is a method of using threonate to alter cellular physiology, such as neuronal physiology. A method of the present disclosure may include providing to a medium comprising a cell, a threonate-containing compound, or a precursor thereof, to increase the concentration of threonate in the medium, where the increased concentration of threonate is sufficient to increase the concentration of magnesium in the cell. Also provided is a method that includes administering a threonate-containing compound, or a precursor thereof, to an individual, to increase synaptic density in the brain and/or to treat a neurological disorder, e.g., cognitive impairment. The threonate-containing compound of the present disclosure does not include magnesium threonate.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: December 3, 2019
    Assignee: Neurocentria, Inc.
    Inventors: Guosong Liu, Fei Mao, Qifeng Sun
  • Patent number: 10493036
    Abstract: A capsule excellent in enteric property with the assumption that gelatin is used as a main base material of the capsule coating. An alkali-treated gelatin and carrageenan are contained as base materials of the capsule coating. In the gastric (aqueous) environment, the alkali-treated gelatin which is positively (+) charged coexists with the carrageenan which is negatively (?) charged, and amino groups (NH4+) in the gelatin react with sulfate groups (SO3?) in the carrageenan so that the capsule coating is insolubilized. On the other hand, in the intestinal (aqueous) environment, the alkali-treated gelatin which is negatively (?) charged coexists with the carrageenan which is negatively (?) charged, and the amino groups (NH4+) in the gelatin are repulsive to the sulfate groups (SO3?) in the carrageenan so that the capsule coating quickly disintegrates and dissolves.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: December 3, 2019
    Assignee: SUNSHO PHARMACEUTICAL CO. LTD
    Inventors: Takayuki Fukasawa, Kenichi Koyama, Tomoya Suzuki
  • Patent number: 10487145
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: November 26, 2019
    Assignee: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Patent number: 10485861
    Abstract: Provided herein are new compositions including an inactivated pathogen and one or more adjuvant-loaded polymeric nanoparticles, wherein the adjuvant-loaded nanoparticles are bound to the inactivated pathogen. These compositions are useful for preventing and/or treating diseases caused by the specific pathogens, especially when administered to a subject's mucosal membranes.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 26, 2019
    Assignees: President and Fellows of Harvard College, Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Georg Stary, Aleksandar Filip Radovic-Moreno, Pamela A. Basto, Michael N. Starnbach, Robert S. Langer, Omid C. Farokhzad, Ulrich Von Andrian
  • Patent number: 10485758
    Abstract: An oral gastro-retentive delivery device is provided which unfolds rapidly upon contact with gastric juice. The device is configured in a collapsed configuration for oral intake and unfolding for gastric retention for a predetermined period of time and eventually reducing in size for passage through the rest of the GI track.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: November 26, 2019
    Assignee: Clexio Biosciences Ltd.
    Inventors: Avshalom Ben Menachem, Ilan Zalit
  • Patent number: 10470478
    Abstract: An protein-polysaccharide macromolecular complex article of manufacture containing encapsulated ethyl alcohol and/or other spirits serving as an entertaining and novel non-beverage method of consuming alcohol. The article of manufacture encapsulates ethyl alcohol and/or other spirits in the amorphous regions of the complex macromolecular structure releasing it only upon chewing and exposure to the environment of the oral cavity. The article of manufacture is stable and capable of retaining shape and form for extended periods of time at ambient temperature allowing for relatively low-cost commercial manufacture and distribution.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: November 12, 2019
    Assignee: CURE PHARMACEUTICAL CORPORATION
    Inventors: Margaret Teresa Thomas Virgallito, Joshua Alan Held
  • Patent number: 10470987
    Abstract: Compositions allowing the stimulation of hyaluronic acid synthesis via an increase in has-2 expression and their use in the treatment of conditions related to a decrease in hyaluronic acid synthesis.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: November 12, 2019
    Assignees: TOMCAT INTERNATIONAL LIMITED, President and Fellows of Harvard College
    Inventors: Bertrand Thomas, Mathilde Thomas, David Sinclair
  • Patent number: 10463739
    Abstract: A formulation comprising a melt-processed solid dispersion product comprising an active agent, a pharmaceutically acceptable thermoplastic polymer of N-vinyl lactams, and a pharmaceutically acceptable polyvinyl alcohol-polyalkylene glycol graft copolymer. A method for producing said formulation.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: November 5, 2019
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Gunther Berndl, Juergen Weis, Dietrich Granzow, Bernd Liepold, Ute Lander, Ulrich Westedt
  • Patent number: 10449148
    Abstract: Compositions that can be used to improve human health, and in particular brain health are provided. In some embodiments the composition comprises Inositol, N-Acetyl L-Tyrosine, pyrroloquinoline quinone (PQQ), Choline bitartrate, L-Theanine and Acetyl-L-Carnitine. The compositions may be administered to a subject, for example in the form of a liquid drink, to improve brain health.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: October 22, 2019
    Assignee: BRAINGEAR ENTERPRISES, INC.
    Inventors: Patricia Gutierrez, Christina Beer
  • Patent number: 10441591
    Abstract: This invention discloses uses for etonogestrel in preparing anti-prostate cancer products. This invention provides uses for etonogestrel in preparing anti-prostate cancer products. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug etonogestrel, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that etonogestrel has a new use as an anti-prostate cancer medication, thus achieving a new purpose for an old drug.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: October 15, 2019
    Assignee: SHANGHAI JIAO TONG UNIVERSITY
    Inventors: Yongyong Shi, Zhijian Song
  • Patent number: 10434139
    Abstract: An oral composition comprising minicapsules wherein the minicapsules comprise one or more therapeutic prophylactic substances in a liquid, semi-liquid, or solid core. The minicapsules have release profiles to release the substance in an active form at one or more sites along the gastro-intestinal tract to maximize absorption and/or therapeutic efficiency.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: October 8, 2019
    Assignee: Sublimity Therapeutics Limited
    Inventor: Ivan Coulter
  • Patent number: 10434140
    Abstract: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilized liquid form. The minicapsules have a release profile to release the pre-solubilized cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: October 8, 2019
    Assignee: Sublimity Therapeutics Limited
    Inventor: Ivan Coulter
  • Patent number: 10432604
    Abstract: A computer-implemented system and method for pool-based identity authentication for service access without use of stored credentials is disclosed. The method in an example embodiment includes providing provisioning information for storage in a provisioning repository; receiving a service request from a service consumer, the service request including requestor identifying information; generating an authentication request to send to an authentication authority, the authentication request including requestor identifying information; receiving validation of an authenticated service request from the authentication authority; and providing the requested service to the service consumer.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: October 1, 2019
    Assignee: eBay Inc.
    Inventors: Raju Venkata Kolluru, Michael Dean Kleinpeter
  • Patent number: 10420773
    Abstract: Methods of treating developmental disorders and/or seizure disorders with etifoxine, a deuterated analog of etifoxine, or a pharmaceutically acceptable salt, solvate, or prodrug thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of the developmental disorder and/or seizure disorder.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: September 24, 2019
    Assignee: OVID THERAPEUTICS INC.
    Inventor: Matthew During
  • Patent number: 10413558
    Abstract: A pharmaceutical composition or kit of parts comprising at least three ingredients from a HMG-CoA reductase inhibitor, a leukotriene antagonist, a proton pump inhibitor, melatonin or a melatonin receptor agonist, a bioavailable preparation of a curcuminoid, a calciferol derivative, a compound from the group consisting of metformin and phenformin, valproate, minocycline and chloroquine and one or more pharmaceutically acceptable carriers or excipients.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: September 17, 2019
    Assignee: TARGETED THERAPIES RESEARCH AND CONSULTING CENTER SPRL
    Inventor: Marc Zeicher
  • Patent number: 10398746
    Abstract: An edible oral film strip dosage form containing an unpalatable basic active pharmaceutical ingredient and an ion exchange resin as a primary taste masking agent, along with an optional acidic agent and further optionally containing one or more secondary taste masking agents is provided. The edible oral film strip dosage matrix is formed from at least one water soluble or miscible polymer(s). The optional secondary taste masking ingredients include one or more of flavoring agent(s), sweetener(s), cooling sensation agent(s), and taste receptor blocker(s). Methods for preparing the inventive edible oral film strip dosage forms are disclosed, as well as their method of administration.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: September 3, 2019
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Michael Li, Markus Krumme
  • Patent number: 10383826
    Abstract: The present invention provides an apparatus and process for making softgel capsules having incorporated therein other solid dosage forms selected from the group consisting of pellets, smaller capsules, smaller tablets, sustained release solid dosage forms, immediate release solid dosage forms, extended release solid dosage forms and zero order release solid dosage forms, said apparatus comprising: (a) two spreader boxes; (b) two casting drums; (c) a pair of rotary dies having means for suction; (d) a liquid fill system; (e) a wedge for heating gelatine ribbons and feeding said fill; and (f) two lateral dispensing devices said lateral dispensing devices including hoppers having said solid dosage forms, channel guides for transporting said solid dosage forms and a grasping claw for dispensing said solid dosage form into the softgel pocket formed in the rotary dies.
    Type: Grant
    Filed: September 5, 2016
    Date of Patent: August 20, 2019
    Assignee: PROCAPS SA
    Inventors: Carlos Salazar Altamar, Gustavo Anaya, Braulio Teran, Newman Aguas Navarro, Wilmer Herrera
  • Patent number: 10376501
    Abstract: Disclosed herein are pharmaceutically acceptable complex formulations comprising complexes of Lumacaftor, or a salt, or derivative thereof together with complexation agents and, optionally, pharmaceutically acceptable excipients; processes for the preparation thereof and pharmaceutical compositions containing them. The complex formulations have improved dissolution and permeability in fasted and fed state simulation that is expected to deliver full absorption and the elimination of the food effect.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: August 13, 2019
    Assignee: Druggability Technologies IP Holdco Limited
    Inventors: Richárd Balázs Kárpáti, Betti Szabóné Ordasi, Orsolya Basa-Dénes, Erzsébet Réka Angi, Tamás Jordán, László Molnár, Hristos Glavinas, Zsolt Ötvös, Genovéva Filipcsei
  • Patent number: 10369111
    Abstract: The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not 5 limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically 10 diabetes, insulin resistance, obesity, hyperlipidemia and hypertension. The present invention restores altered probiotic organism imbalances that are characteristic of said diseases among others as well as defines a platform technology development for site specific delivery of probiotic organisms in the GI tract of a 15 mammal, most specifically the ileum and/or right colon of a human subject.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: August 6, 2019
    Assignee: Therabiome, LLC
    Inventors: Mohan Kabadi, Jerome J. Schentag
  • Patent number: 10369340
    Abstract: Devices and methods for administering a therapeutic agent, including an implantable delivery device. Exemplary embodiments include a reservoir in fluid communication with a channeled member, and a compound including the therapeutic agent and a solubilizer disposed within the reservoir.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: August 6, 2019
    Assignee: NANOMEDICAL SYSTEMS, INC.
    Inventors: Michael Crowley, Randy Goodall, Lee Hudson
  • Patent number: 10363220
    Abstract: The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: July 30, 2019
    Assignee: Triastek, Inc.
    Inventor: Xiaoling Li
  • Patent number: 10357455
    Abstract: A pharmaceutical composition comprises a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer and a lipophilic microphase-forming material. Alternatively, a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer is co-administered with a lipophilic microphase-forming material to an in vivo use environment.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: July 23, 2019
    Assignee: Bend Research, Inc.
    Inventors: Michael E. Perlman, Ravi M. Shanker, Walter C. Babcock, Dwayne Thomas Friesen, Mark D. Rabenstein, Daniel Tod Smithey
  • Patent number: 10350296
    Abstract: Chewable gelatin formulations that include a bovine gelatin and a fish gelatin.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: July 16, 2019
    Assignee: Aspire Pharmaceuticals
    Inventors: Madhav Pai, Ritesh Patel
  • Patent number: 10342848
    Abstract: This invention provides a method of colonic cleansing.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: July 9, 2019
    Assignee: BAUSCH HEALTH IRELAND LIMITED
    Inventors: Dennis Riff, Gary S. Jacob, Kunwar Shailubhai, Patrick H. Griffin
  • Patent number: 10347158
    Abstract: A dissolvable produce washing label includes a dissolvable facestock impregnated with a produce cleanser; an adhesive layer; and a coating to seal and protect from water and humidity. When rubbed and washed with water by the end user the top coating wears and breaks to expose the dissolvable substrate, thereby dissolving the facestock and releasing the produce wash.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: July 9, 2019
    Inventor: Scott Amron
  • Patent number: 10335371
    Abstract: The present invention relates to solid pharmaceutical dosage forms suitable for use as drinking water medication. More in particular, the present invention provides solid pharmaceutical dosage forms comprising a pharmaceutically active agent, a non-ionic surfactant having an Hydrophilic Lipophilic Balance (HLB) of at least 8, and a maltodextrin. The present invention also provides the use of such pharmaceutical dosage forms in veterinary medicine, more in particular as drinking water medication; as well as methods for preparing such pharmaceutical dosage forms.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: July 2, 2019
    Assignees: Universiteit Gent, Orotech NV
    Inventors: Jean-Paul Remon, Chris Vervaet, Brenda Vermeulen
  • Patent number: 10336817
    Abstract: A therapeutic composition of camel milk can include an herbal composition having solid material or liquid extracts from the solid material of at least one of Saussurea acrophila Diels, Saussurea ceratocarpa, and Aucklandia lappa Decne. The solid material may include one or more of parts or the whole of the stem, the bark, the flowers and the roots of one or more, but preferably all of Saussurea acrophila Diels, Saussurea ceratocarpa, and Aucklandia lappa Decne. The therapeutic composition can include camel milk, alone, or in combination with the herbal composition. The camel milk can be HIV-immunized camel milk. The HIV-immunized camel milk can be obtained by immunizing a camel against HIV by administering to the camel the modified DNA plasmids of SEQ. ID No.: 3 and SEQ ID No.: 4 and obtaining the milk from the immunized camel.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: July 2, 2019
    Assignee: Sultan Qaboos University
    Inventors: Sidgi Syed Anwer Abdo Hasson, Ali A. H. Al-Jabri
  • Patent number: 10328087
    Abstract: Compositions and methods for the solubilization of steroid hormones are disclosed.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: June 25, 2019
    Assignee: TherapeuticsMD, Inc.
    Inventors: Thorsteinn Thorsteinsson, Frederick D. Sancilio, Brian A. Bernick, Julia M. Amadio
  • Patent number: 10328038
    Abstract: The present technology provides siderophore-polymer conjugates that enhance the sensitivity of bacteria to antibiotics, e.g., Pseudomonas, P. aeruginosa, Acinetobacter, and A. baumannii.Methods of preparing and using such conjugates to treat bacterial infections are disclosed.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: June 25, 2019
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: May Xiong, Max Purro